학술논문
Physical and cognitive impact following SARS-CoV-2 infection in a large population-based case-control study.
Document Type
Academic Journal
Author
Holm H; deCODE genetics/Amgen Inc., Reykjavik, Iceland. hilma.holm@decode.is.; Ivarsdottir EV; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Olafsdottir T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Thorolfsdottir R; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Eythorsson E; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Norland K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Gisladottir R; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; School of Humanities, University of Iceland, Reykjavik, Iceland.; Jonsdottir G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Unnsteinsdottir U; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Sveinsdottir KE; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Jonsson BA; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Andresdottir M; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Arnar DO; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Arnthorsson AO; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Birgisdottir K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Bjarnadottir K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Bjarnadottir S; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Bjornsdottir G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Einarsson G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Eiriksdottir B; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Gardarsdottir EE; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Gislason T; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Gottfredsson M; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Gudmundsdottir S; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Gudmundsson J; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Gunnarsdottir K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Helgadottir A; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Helgason D; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Hinriksdottir I; National Institute of Hearing and Speech in Iceland, Reykjavik, Iceland.; Ingvarsson RF; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Jonasdottir SS; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Jonsdottir I; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Karlsdottir TH; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Kristinsdottir AM; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Kristinsson SY; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Kristjansdottir S; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Love TJ; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Ludviksdottir D; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Masson G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Norddahl G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Olafsdottir T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Olafsson I; Clinical Laboratory Services, Diagnostics and Blood Bank, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Rafnar T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Runolfsdottir HL; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Saemundsdottir J; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Sigurbjornsson S; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Sigurdardottir K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Sigurdsson E; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Mental Health Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Sigurdsson MI; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Perioperative Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Sigurdsson EL; Department of Family Medicine, University of Iceland, Reykjavik, Iceland.; Development Centre for Primary Health Care in Iceland, Reykjavik, Iceland.; Steinthorsdottir V; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Sveinbjornsson G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Thorarensen EA; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Thorbjornsson B; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Thorsteinsdottir B; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Tragante V; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Ulfarsson MO; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Faculty of Electrical and Computer Engineering, University of Iceland, Reykjavik, Iceland.; Stefansson H; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Gislason T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Kristjansson M; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Palsson R; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Sulem P; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Thorsteinsdottir U; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Thorgeirsson G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.; Gudbjartsson DF; deCODE genetics/Amgen Inc., Reykjavik, Iceland.; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.; Stefansson K; deCODE genetics/Amgen Inc., Reykjavik, Iceland. kstefans@decode.is.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. kstefans@decode.is.
Source
Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Background: Persistent symptoms are common after SARS-CoV-2 infection but correlation with objective measures is unclear.
Methods: We invited all 3098 adults who tested SARS-CoV-2 positive in Iceland before October 2020 to the deCODE Health Study. We compared multiple symptoms and physical measures between 1706 Icelanders with confirmed prior infection (cases) who participated, and 619 contemporary and 13,779 historical controls. Cases participated in the study 5-18 months after infection.
Results: Here we report that 41 of 88 symptoms are associated with prior infection, most significantly disturbed smell and taste, memory disturbance, and dyspnea. Measured objectively, cases had poorer smell and taste results, less grip strength, and poorer memory recall. Differences in grip strength and memory recall were small. No other objective measure associated with prior infection including heart rate, blood pressure, postural orthostatic tachycardia, oxygen saturation, exercise tolerance, hearing, and traditional inflammatory, cardiac, liver, and kidney blood biomarkers. There was no evidence of more anxiety or depression among cases. We estimate the prevalence of long Covid to be 7% at a median of 8 months after infection.
Conclusions: We confirm that diverse symptoms are common months after SARS-CoV-2 infection but find few differences between cases and controls in objective parameters measured. These discrepancies between symptoms and physical measures suggest a more complicated contribution to symptoms related to prior infection than is captured with conventional tests. Traditional clinical assessment is not expected to be particularly informative in relating symptoms to a past SARS-CoV-2 infection.
(© 2023. The Author(s).)
Methods: We invited all 3098 adults who tested SARS-CoV-2 positive in Iceland before October 2020 to the deCODE Health Study. We compared multiple symptoms and physical measures between 1706 Icelanders with confirmed prior infection (cases) who participated, and 619 contemporary and 13,779 historical controls. Cases participated in the study 5-18 months after infection.
Results: Here we report that 41 of 88 symptoms are associated with prior infection, most significantly disturbed smell and taste, memory disturbance, and dyspnea. Measured objectively, cases had poorer smell and taste results, less grip strength, and poorer memory recall. Differences in grip strength and memory recall were small. No other objective measure associated with prior infection including heart rate, blood pressure, postural orthostatic tachycardia, oxygen saturation, exercise tolerance, hearing, and traditional inflammatory, cardiac, liver, and kidney blood biomarkers. There was no evidence of more anxiety or depression among cases. We estimate the prevalence of long Covid to be 7% at a median of 8 months after infection.
Conclusions: We confirm that diverse symptoms are common months after SARS-CoV-2 infection but find few differences between cases and controls in objective parameters measured. These discrepancies between symptoms and physical measures suggest a more complicated contribution to symptoms related to prior infection than is captured with conventional tests. Traditional clinical assessment is not expected to be particularly informative in relating symptoms to a past SARS-CoV-2 infection.
(© 2023. The Author(s).)